COMPOSITION
Each capsule contains:
Talazoparib …………………………………… 1mg
INDICATION
LuciTala is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of:
- Adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or metastatic breast cancer, as determined by an approved diagnostic test.
- Adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), in combination with enzalutamide.
DOSAGE AND USE
For adult patients with gBRCAm, HER2-negative, locally advanced or metastatic breast cancer, the recommended dosage of LuciTala is 1 mg orally once daily, until disease progression or unacceptable toxicity.
For adult patients with HRR gene-mutated mCRPC, the recommended dosage is 0.5 mg orally once daily in combination with enzalutamide, until disease progression or unacceptable toxicity.
Take LuciTala with or without food. Swallow capsules whole. Do not open or dissolve the capsules.
DOSAGE FORMS AND STRENGTHS
Capsules: 0.25 mg, 0.5 mg, 1 mg
STORAGE
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F).
Keep medicine out of the reach of Children.
MANUFACTURED BY
LUCIUS PHARMACEUTICALS (LAO) CO., LTD
No. 26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION
To be sold by retail on prescription of a Registered physician only, and as directed by the physician. Keep medicine out of reach of Children. Do not administer LuciTala during Pregnancy and Lactation.
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/lucitala-talazoparib-1mg/
Related News
-
LuciTala Side Effects — Blood Count Changes and Clinical Trial Safety
Introduction Cancer medicines can affect patients in different ways. Some side effects…
2026-11-06
-
LuciTala Dosage and Administration — How to Take Talazoparib Safely
Introduction Taking an oral cancer medicine at home can be convenient, but…
2026-11-04
-
LuciTala (Talazoparib): How PARP Inhibition Works in Certain Cancers
Introduction A cancer diagnosis often brings difficult questions about treatment, expected outcomes…
2026-11-02
-
LuciNav Side Effects — Hyperglycaemia, Risks and Patient Monitoring
Introduction Targeted cancer medicines are designed to act on particular biological pathways,…
2026-10-31
-
How to Take LuciNav Safely — Dosage, Monitoring and Precautions
Introduction Taking an oral cancer medicine involves more than following a daily…
2026-10-26
-
LuciNav (Inavolisib) for PIK3CA-Mutated Breast Cancer
Introduction A breast cancer diagnosis can bring uncertainty, particularly when the disease…
2026-10-21



